
    
      This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus
      bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS
      wild-type tumors. In this study the investigators employed deepness of response as a primary
      endpoint.
    
  